- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04770701
Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes
Extracts of Plants Eclipta Prostrata, Dioscorea Cirrhosa, Phyllanthus Urinaria, Adenosma Glutinosum, Impatiens Balsamina and Ascorbic Acid Use for in Protecting and Increasing CD4+ T Lymphocytes; B Lymphocytes Level in HIV/AIDS Patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dioscorea cirrhosa, impatiens balsamina, eclipta prostrata, phyllanthus urinaria, adenosma glutinosum, and ascorbic acid are used to elevate T and B lymphocytes level, protect their cells membrane, decrease the damage of HIV on CD4+ T.
In detail, Diosgenin presented in dioscorea cirrhosa is a precursor of cortisol. Dioscorea cirrhosa when combined with ascorbic acid helps to balance cortisol levels which reduces cell inflammation. Flavonoids of dioscorea cirrhosa also help to increase CD4+ T levels.
impatiens balsamina can be used as an antitoxin alternative against bacteria or viruses. Flavonoids in impatiens balsamina, such as kaempferol, quercetin, rutin, astragalin, have the ability to reduce the virus's impact on T lymphocyte, protect their cell membrane, produce antihistamine, protect the cell from inflammation.
Targeted flavonoids in eclipta prostrata, phyllanthus urinaria, adenosma glutinosum are used to cell repair, protect and increase CD4+ T production.
Ascorbic acid in combination with herbal extracts creates a favorable environment for body metabolism, improves the medication's effectiveness.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Ho Chi Minh City, Vietnam, 700000
- Saigon Biopharma Company Limited
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants have a decline in CD4 + T-lymphocytes is the hallmark of HIV-1 infection.
Characterized by rapid loss of resistance: AIDS
- Dermatitis, mouth ulcers, skin rash, itching, weight loss
- HCV (+), HBV (+), Tuberculosis (+)
Exclusion Criteria:
- Cancer under all form
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ahah drug
Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection. Characterized by rapid loss of resistance: AIDS
Ahah composition contains the following ingredients (concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg |
- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg -Take 1tablet x 2 times / 24 hours. Maintained for 9 months.
Other Names:
|
EXPERIMENTAL: Ahah Placebo
Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection. Characterized by rapid loss of resistance: AIDS
Ahah composition placebo (Ahah not containing concentrated extracts of plants Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg) |
- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg) -Take 1tablet x 2 times / 24 hours. Maintained for 9 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The CD4 cell count measurement
Time Frame: - 9 months
|
HIV is a fatal infection, characterized by the targeting and destruction of CD4 T lymphocytes in the peripheral blood.
|
- 9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tran Minh Duc, Dr., Trieu, Nguyen Thi, M.D.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HIV / AIDS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on Ahah Drug
-
JW PharmaceuticalCompleted
-
GlaxoSmithKlineCompleted
-
CelltrionCompletedHealth, SubjectiveKorea, Republic of
-
Novus Therapeutics, IncCompletedHealthy Adult VolunteersUnited States
-
JW PharmaceuticalCompleted
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
University of ZurichUniversity Hospital, Zürich; Center of Competence Multimorbidity, ZurichCompletedDiabetes Complications | Gastrointestinal Hemorrhage | MultimorbiditySwitzerland
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAxial SpondyloarthritisUnited States
-
Sahlgrenska University Hospital, SwedenUppsala University; The Swedish Research Council; Swedish Heart Lung Foundation; The Swedish National Registry for Vascular SurgeryActive, not recruitingPeripheral Arterial Disease | Intermittent Claudication | Critical Limb IschemiaSweden
-
Bon-Kwon KooSeoul St. Mary's Hospital; Chonnam National University Hospital; Seoul National... and other collaboratorsRecruitingCoronary Artery Disease | Multi Vessel Coronary Artery DiseaseKorea, Republic of